|
Understanding cancer development and progression
Chair: C. Burger, Merck KGaA, Darmstadt/D
|
09:00 |
Keynote Lecture
Modelling Wnt signalling in 3D culture
T. Dale, Cardiff University/UK
|
09:45 |
A novel culture strategy to model tumour microenvironment dynamics and study tumour-stroma interactions and disease progression
M. Estrada¹; S. Rebelo¹; V. Santo¹; S. Abreu¹; E. Davies²; M. Pinto³; H. Pereira⁴; M. Smalley2; S. Barry5; E. Gualda⁴; P. Alves¹; E. Anderson6; C. Brito¹
¹ iBET/ITQBAX-UNL, Oeiras/P; ² Bioscience, Oncology iMed, AstraZeneca, Chesire/UK; ³ Institute of Molecular Pathology and Immunology, Porto/P; ⁴ Instituto Gulbenkian de Ciência, Oeiras/P; 5 European Cancer Stem Cell Institute, Cardiff/UK; 6 Boehringer Ingelheim, Vienna/A
|
10:05 |
Establishment of a standardized 3D in vitro tumor-stroma model
M. Mueller¹; S. Hensler¹; B. Kotkamp¹; K. Pohl²; N. Linde³; D. Stoll⁴
¹ Hochschule Furtwangen, Villingen-Schwenningen/D; ² NMI Reutlingen/D; ³ Mount Sinai School of Medicine, New York/USA; ⁴ Hochschule Albstadt-Sigmaringen/D
|
10:25 |
Coffee Break |
|
Advanced models for substance testing: cancer therapy
Chair: T. Noll, University of Bielefeld/D
|
11:00 |
The Spheroid microtumor model is predictive for the therapeutic response in neoadjuvant breast cancer (SpheroNEO study)
K. Halfter¹; N. Ditsch²; B. Mayer³
¹ SpheroTec GmbH, Munich/D; ² Frauenklinik, Klinikum Großhadern, Munich/D; ³ Klinikum Großhadern, Munich/D
|
11:20 |
Multi-parametric 3D tumor microtissue-based phenotypic compound classification
J. Kelm¹; Z. Weydert¹; M. Lal²; L. Mathews Griner²; C. Schmees³; B. Gierke³; M. Pawlak³; H. Cordes⁴; C. Thiel⁴; M. Ferrer²
¹ Insphero AG, Schlieren/CH; ² NCATS/NIH, Rockville/USA; ³ NMI Technologietransfer GmbH, Reutlingen/D; ⁴ RWTH Aachen University/D
|
11:40 |
Conditionally immortalized human endothelial cells for the investigation of KSHV latency and intervention in novel in vitro and in vivo models
T. Dubich¹; C. Lipps¹; M. Butueva¹; T. May²; D. Wirth¹
¹ Helmholtz Centre for Infection Research, Braunschweig/D; ² InSCREENeX GmbH, Braunschweig/D
|
12:00 |
Lunch / Poster / Exhibition
|
|
From the potential of organoids to multi-organ platforms
Chair: T. May, InSCREENeX GmbH, Braunschweig/D
|
14:00 |
Keynote Lecture
Organoids: An in vitro culture for all patients
R. Vries, foundation Hubrecht Organoid Technology, Utrecht/NL
|
14:45 |
Emulating the human vasculature in a multi-organ-chip platform
T. Hasenberg¹; K. Schimek²; S. Mühleder³; A. Dotzler¹; S. Bauer²; K. Labuda3; W. Holnthoner3; H. Redl3; R. Lauster²; U. Marx¹
¹ TissUse GmbH, Berlin/D; ² Technische Universität Berlin/D; ³ Austrian Cluster for Tissue Regeneration, Vienna/A
|
15:05 |
Adding metabolic competence to 3D spheroid-based assays by using a microfluidic multi-tissue culturing platform
O. Frey¹; J. Kim¹; A. Hierlemann¹; D. Fluri²; J. Kelm²; T. Petreus³; E. Tang³; R. Marchan⁴; J. Hengstler⁴
¹ ETH Zürich, Basel/CH; ² InSphero, Schlieren/CH; ³ AstraZeneca, Cheshire/UK; ⁴ IfaDo, Dortmund/D
|
15:25 |
Coffee Break
|
|
Assays and devices
Chair: M. Rimann, Zurich University of Applied Science,
Wädenswil/CH
|
16:00 |
Immortalized lung epithelial cells with in vivo like characteristics
T. May¹; T. Herfurth¹; R. Schucht¹
¹ InSCREENeX GmbH, Braunschweig/D
|
16:20 |
Designing assays and appropriate controls to interrogate 3D culture models
T. Riss¹
¹ Promega Corporation, Madison/USA
|
16:40 |
The Nunclon Sphera surface supports formation of three dimensional cancer spheroids in suspension
P. Reuter¹; C. Neeley²; L. Gaarn²
¹ Thermo Fisher Scientific, Langenselbold/D; ² Thermo Fisher Scientific, Rochester/USA
|
|
Advanced model systems: brain
Chair: M. Rimann, Zurich University of Applied Science,
Wädenswil/CH
|
17:00 |
Keynote Lecture
Modelling human neuronal maturation in 3D
I. Galimberti, Novartis Pharma AG, Basel/CH
|
17:45 |
End of lecture programme of Day 2 |
19:00 |
Conference Dinner, Historisches Kaufhaus |